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ORIGINAL ARTICLE
INTRODUCTION
Colorectal polyps (CP) are classified histologically
as neoplastic (adenomas) and non-neoplastic type.1,2
Most studies support CP being considered precursors
to the development of colorectal cancer (CRC).3-5
The incidence of adenomas and carcinomas of the colon
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is high in western Europe and the United State in
contrast to the low incidence of both among
populations of Afro-Asian origin.5-9 There are some
differences between CRC in developed countries and
in Indonesia. The prevalence of CRC in developed
countries in patients aged 50 years or less was
3.1-8.6%,1,3 while in Indonesia, the proportion of CRC
patients aged 40 years or less was higher.2 Another
point is, the young onset CRC in western population
commonly associated with a positive family history,10,11
involving germ-line mutations of mismatch repair
(MMR) genes, following microsatellite instability
(MSI) pathway,12 while young CRC Indonesian
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patients did not show any positive family history and
there was no difference in term of expression of MMR
proteins compared with older patients.13 Abdullah
concluded that colorectal carcinogenesis of young
patients seems to be the same as in elder patients and
might follow a sporadic pathway.14 It is thought that
chronic process gives conducive microenvironment
milieu for inducing malignant changes of epithelial
cells.15 In this inflammatory-induced carcinogenesis
pathway, the nuclear factor kappa B (NF-κB), which
is an important mediator of the growth and
development of inflammatory-induced tumorigenesis,16
could well be an important player since it is activated
in chronic inflammation, and might involved dysplastic
epithelial cells rather than adenoma.17-19
In sporadic cancers, mutations may occur through
different types of molecular alterations induced by
carcinogens, tumor promoters, carcinogenic viral
proteins, chemotherapeutic agents, and γ-irradiation.
The alterations involved irregulation of NF-κB
activation and pro-inflammatory gene products such
as tumor necrosis factors (TNF) and members of its
superfamily, IL-1a, IL-1b, IL-6, IL-8, chemokines,
matrix metallopeptidase 9 (MMP-9), vascular
endothelial growth factor (VEGF), cyclooxygenase-2
(COX-2), and 5-lipoxygenase (5-LOX), that
participate in the development and progression of
cancer and mediate a critical role in suppression of
apoptosis, proliferation, angiogenesis, invasion,
and metastasis.20-25 COX-2 may have a crucial
involvement in intestinal carcinogenesis by inducing
changes in cellular adhesion, local invasion, and
inhibition of apoptosis, and is upregulated in
consecutive stages of the colorectal adenoma-
carcinoma sequence in patients with sporadic
colorectal cancer and in familial adenomatous
polyposis.16,18,26,27 However, COX-2 enzyme was not
expressed in 61% of CRC patients with high MSI or
negative expression of MMR proteins.28 COX-2 is not
detectable in most normal tissues, but it is induced at
inflammation area by epithelial injury as part of
inflammatory response to infections such as cytokines,
growth factors, tumor promoters and other s
timuli.26,29-31 COX-2 expression was associated
with other inflammatory markers, such as interleukin
(IL)-1β, IL-6 and sub-unit p65 NF-κB both in the
epithelial or stromal cells27 suggesting that
inflammatory process play roles in sporadic colorectal
carcinogenesis.14,19
Molecular studies of inflammatory markers in CP
in Indonesia are limited. So far, as our knowledge there
is no study assessing the role of NF-κB and COX-2 in
neoplastic and non-neoplastic cases. This study was
aimed to explore the expression pattern NF-κB and
COX-2 in Indonesian patients and to compare
their expressions between neoplastic and non-
neoplastic CP. Finding of such relation will assist in
developing new modalities in the course of preventive
and curative efforts for CRC, which are considered
as chemoresistant tumors.32 In addition, this study will
provide data for further study about chemoprevention
of colorectal cancer.
METHOD
Study Materials
The study was performed on archived human
paraffin-embedded polypectomy tissue sections from
medical record in the Department of Anatomical
Pathology at Cipto Mangunkusumo hospital, Jakarta
in the year 2007 and 2008. All of the hematoxylin
and eosin-stained glass slides of these cases were
reviewed by a single pathologist to confirm the
histopathologic diagnosis in each case. The samples
were excluded if histological findings revealed the
presence of malignancy, if the available tissue
sections were damaged, and if the patient medical
record were missing.
Immunohistochemistry
Four-µm-thick step sections of representative
formalin-fixed paraffin-embedded tissue blocks
were prepared for immunohistochemical analysis.
NF-κB and COX-2 expressions were evaluated
using the avidin/biotin complex immunohistochemistry
procedure.31 We used rabbit polyclonal antibodies
against human NF-κB p65 subunit (RelA) (Cat
No.#ab7970, Abcam, UK) and human COX-2 protein
(Cat No.#ab15191, Abcam, UK) as primary antibodies.
Sections were sequentially deparaffinized and
rehydrated through xylene and graded alcohol
solutions. Then, slides were pretreated with epitope
retrieval system and preheated in a microwave for 5
minutes. Afterwards, slides were immersed in
phosphate buffer saline (PBS) for 5 minutes.
Endogenous peroxidase activity was blocked by
immersing the sections into a solution mixture of
hydrogen peroxide 3% and methanol for 10 minutes in
refrigerator, and then were rinsed with PBS for 5
minutes. Slides were marked by a Pap pen and then
were put again in PBS. After removal from PBS, slides
were placed in a treatment chamber. Blocking
solution was applied into each section and the
chamber was closed for 10 minutes. Primary antibodies
were diluted in distilled water with 1:100 for COX-2
and 1:150 for NF-κB. Sections were then incubated
with primary in the treatment chamber for 45 minutes.
After washing with PBS, antibody binding was detected
by incubation with bitinylated secondary antibody for
10 minutes. Then the slides were washed again with
PBS and incubated with straptavidin-horse radish
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peroxydase. Staining was developed by applying the 
chromogen 3.3 diaminobenzidine in distilled water and  
then counterstain with hematoxylin. Finally, specimens  
were dehydrated and mounted. Positive and internal  
negative controls were included in each staining.  
Internal negative control sections run without the  
addition of primary antibodies. Positive control was  
fibroblast cells known to have positive COX-2  
expression. 
Evaluation of Immunostaining 
The immunostaining reactions were evaluated for  
NF-κB and COX-2 expressions in the lesions, with  
light microscopy. The periluminal expression of  
NF-κB and COX-2 observed in polyps was scored.  
The scoring was accomplished according to area of  
staining (0-4) + intensity (0-3) in each polyp. Then,  
the NF-κB and COX-2 expression scores were  
correlated each other. The NF-κB and COX-2  
expression were classified as low, if the scores were  
5 or lower, and classified as high if the scores were  
six or higher. After classification, the expressions were  
correlated with histopathogical type, location of CP,  
and age of the patients. 
Statistical Analysis 
Statistical analysis was performed using SPSS 17  
(SPSS Inc, Chicago, IL). Clinical characteristics in CP  
were analyzed using chi-square and logistic regression. 
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Correlation between the NF-κB and COX-2 expression 
score was analyzed using Pearson test. Analysis of 
NF-κB and COX-2 expression in relation with patient’s 
age, type, and location of CP were done using logistic 
regression. The difference between groups were 
considered significant if p < 0.05. 
RESULTS 
A total number of 77 CPs were diagnosed in the  
2007-2008. There were 39 (50.6%) males, and 38  
(49.4%) female patients with age range from 17 to 86  
years with mean age ± SD of 54.8 ± 15.9 (table 1).  
There were no significant difference of frequency  
between non-neoplastic and neoplastic CP in terms of  
patient’s age, and location of CP. In addition, there  
was no apparent correlation between non-neoplastic  
and neoplastic CP in expression of NF-κB and  
COX-2. However, there was good correlation between  
NF-κB and COX-2 expression scores of CP in  
general (table 2). There was no significant difference  
between expression of NF-κB in terms of patient’s  
age, type, and location of the CP (table 3). Although  
there was no significant difference between  
expression of COX-2 in terms of type and location of  
CP, but there was significantly higher COX-2  
expression in the group of CP patients aged < 50 years  
as compared with patients aged 50-59 and above 60  
years (table 4). 
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Table 1. Characteristic of the 77 patients with CPs 
Clinical characteristics Non-neoplastic Neoplastic p OR (95% CI) 
n (%) n (%) 
Sex 
Male 15 (38.46) 24 (61.54) 
Female 7 (18.42) 31 (81.58) 0.08 
Location 
Proximal 7 (46.67) 8 (53.33) 
Distal 15 (24.19) 47 (75.81( 0.11 
NF-κB expression 
 Low 4 (19.05) 17 (80.95) 
 High 18 (32.14) 38 (67.86) 0.39 
COX-2 expression 
   Low 3 (18.75) 13 (81.25) 
High 19 (31.15) 42 (68.85) 0.54 
Age (years) 
<50 10 (37.04) 17 (62.96) Reference 
50-59 4 (22.22) 14 (77.78) 0.30 2.06 (0.53-8.01) 
> 60 8 (25.00) 24 (75.00) 0.32 1.77 (0.58-5.40) 
OR: Odd Ratio, CI: Confidence Interval 
 
Table 2. NF-κB and COX-2 expression scores 
 
Mean ± SD Correlation p 
NF-kB 5.10 ± 1.40 0.63 p = 0.00 COX-2 5.80 ± 1.40 
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DISCUSSION 
In the present study, we found high expression of  
NF-κB and COX-2 in CPs. This hints at a potential  
role for NF-κB in the regulation of expressed COX-2  
protein in CP, and clinically. This finding strongly  
corroborates the previous findings where there was  
greater NF-κB and COX-2 expression in human  
colorectal adenoma than in adjacent normal colonic  
mucosa. There are several evidence that COX-2 might  
be a rate-limiting step in colon carcinogenesis. Firstly,  
COX-2 inhibit apoptosis in colon tumor cell lines and  
malignant colon tissue. COX-2 inhibitors exert their  
antiproliferative effects in mouse models for CRC and  
in colon tumor cell lines most likely via induction of  
apoptosis. Secondly, inhibition of COX-2 in mice with  
a defective adenomatous polyposis coli (APC) tumor  
suppressor gene, protects against the development of  
intestinal tumors. Thirdly, epidemiological evidence  
shows that individuals who take non-steroidal anti  
inflammatory drugs (NSAIDs) have a markedly  
reduced risk of developing CRC and its presumed non- 
malignant precursor, the adenomatous polyp. Finally,  
expression of COX-2 was found to correlate with an  
unfavorable progression of the disease.27 Expression  
of COX-2 parallels expression of transcription factor  
NF-κB.  These  observations  suggest  that  
immunomodulatory approaches and/or modulation of  
NF-κB expression and activation could be possible  
pharmacological strategies to interfere with the  
development andprogression of CP. 
McLean also found significant increase in 
 
 
 
 
 
 
 
 
 
 
 
 
COX-2 expression in colonic polyps.33 We found a 
good correlation of NF-κB and COX-2 in CP, however  
we found no apparent difference of NF-κB and COX- 
2 between neoplastic and non-neoplastic CP. This fact  
showed that in this study. First, NF-κB are involved in  
COX-2 induction in CP, and second, in non-neoplastic  
CP, inflammation might play an important role.  
Studies with an attempt to find the relationship between  
chronic colonic inflammation and CP are needed.  
Charalambous found high expression of NF-κB and  
COX-2 in neoplastic colorectal epithelial cells, with the  
expression of COX-2 and NF-κB highly correlated.34  
In our study COX-2 expression occur both in  
neoplastic and non-neoplastic cases. Our finding was  
synchronous with previous studies done in Jakarta.14  
Another thing to remind is that patients above 50 years  
of age expressed COX-2 significantly higher than the  
younger ones. 
The proportion of the neoplastic type was slightly  
higher than the non-neoplastic type in our study. This  
was also the case in the west, where the neoplastic  
type makes around 80-85%. Brazowsky et al have  
shown that expression of COX-2 in familial juvenile  
polyps was associated with dysplasia,35 while in our  
study it was not the case. The reason was that they  
worked on familial juvenile polyps only, while in the  
present study we included all types of polyps. We must  
put a stress, however, that our study was not designed  
to find the prevalence of neoplastic polyps in the entire  
CPs population, as we were well aware of the  
limitations of a retrospective study design, this study  
was designed primarily to explore the expression  
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Table 3. NF-kB expression in relation with patient's age, type, and location of CP 
Characteristics 
NF-kB expression OR (CI) p Low High 
n (%) n (%) 
 
 
Age (years) 
<50   5 (18.52) 22 (81.48) Reference 
 50-59 6 (33.33) 12 (66.67) 0.46 (0.11-1.81) 0.26 
> 60 10 (15.15) 56 (84.85) 0.50 (0.15-1.70) 0.27 
    Type Non-neoplastic 4 (18.18) 18 (81.82) Reference 
0.26 Neoplastic 17 (30.91) 38 (69.09) 0.50 (0.15-1.69) 
   Location Proximal 6 (40.00) 9 (60.00) Reference 
 
  Distal 15 (24.19) 47 (75.81) 2.09 (0.64-6.83) 0.22 
 
Table 4. COX-2 expression in relation with patient's age, type, and location of CP 
COX-2 expression OR (CI) p Characteristics Low High 
  
n (%) n (%) 
 
 
Age (years) 
<50   1 (3.70) 26 (96.30) Reference 
 50-59 6 (33.33) 12 (66.67) 0.08 (0.01-0.71) 0.02 
≥ 60 9 (28.13) 23 (71.87) 0.10 (0.01-0.84) 0.03 
  
  Type Non-neoplastic 3 (13.64) 19 (86.36) Reference 0.33 Neoplastic 13 (23.64) 42 (76.36) 0.51 (0.13-2.00) 
    
Location Proximal 2 (13.33) 13 (86.67) Reference 
 
  Distal 14 (22.58) 48 (77.42) 0.53 (0.11-2.6) 0.43 
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pattern NF-κB and COX-2 in Indonesian patients and
to compare their expressions between neoplastic and
non-neoplastic CP. Nevertheless, the present study
provides important information on this particular
subset of patients.
CONCLUSION
The expression of NF-κB and COX-2 in patients
with CP were high, and strong correlated each other.
There were no significant differences between
expression of NF-κB and COX-2 in neoplastic and
non-neoplastic polyps.
SUGGESTION
The expressions of NF-κB and COX-2 in patients
with CP were high, and well correlated each other.
This finding led us to identify who is at risk of NF-κB
and COX-2-expressing CP and for new drugs that can
provide benefits for CP patients without the risks
associated with the drug. The differences between CP
that expresses high or low levels of NF-κB and
COX-2 have to be investigated, and this understanding
can form the basis for clinical implications. This study
describes the expression of COX-2 in CP. COX-2
overexpression appears as a rationale for the
chemoprevention in CP and immunomodulatory
approaches and/or modulation of NF-κBexpression.
There were no significant differences between
expression of NF-κB and COX-2 in neoplastic and
non-neoplastic polyps. This finding led us to be aware
of that even in non-neoplastic CP there was high
percentage of NF-κB and COX-2 expression.
Further, in future NF-κBand COX-2 expression are
suggested to be included in routine investigations for
colorectal growth and some other tumors.
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